PrairieView Partners’s Fulcrum Therapeutics FULC Stock Holding History

PrairieView Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$34K	Hold	5,000	–	–	﹤0.01%	212
2025 Q1	$14K	Hold	5,000	–	–	﹤0.01%	262
2024 Q4	$23K	Hold	5,000	–	–	﹤0.01%	236
2024 Q3	$17K	Hold	5,000	–	–	﹤0.01%	257
2024 Q2	$31K	Hold	5,000	–	–	﹤0.01%	231
2024 Q1	$48K	Hold	5,000	–	–	0.01%	192
2023 Q4	$34K	Hold	5,000	–	–	﹤0.01%	202
2023 Q3	$22K	Hold	5,000	–	–	﹤0.01%	236
2023 Q2	$16K	Buy	5,000 +1,400	+39%	+$4.11K	﹤0.01%	285
2023 Q1	$10K	Hold	3,600	–	–	﹤0.01%	304
2022 Q4	$26K	Hold	3,600	–	–	﹤0.01%	236
2022 Q3	$29K	Buy	3,600 +1,400	+64%	+$10K	﹤0.01%	222
2022 Q2	$11K	Buy	2,200 +1,700	+340%	+$16.6K	﹤0.01%	318
2022 Q1	$12K	Buy	500 +300	+150%	+$4.25K	﹤0.01%	311
2021 Q4	$4K	Buy	+200	New	+$3.96K	﹤0.01%	364

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PrairieView Partners's FULC Position: Q2 2025 in Review

PrairieView Partners held its Fulcrum Therapeutics (FULC) position steady in Q2 2025 at 5,000 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #212.

PrairieView Partners first reported a position in FULC in Q4 2021 and has held it in 15 quarters since. The position peaked at $48K in Q1 2024. 122 funds tracked by Wall St. Rank hold FULC as of Q2 2025.

PrairieView Partners held 5,000 shares of Fulcrum Therapeutics worth $34K as of Q2 2025.
PrairieView Partners left its Fulcrum Therapeutics share count unchanged in Q2 2025.
Fulcrum Therapeutics made up ﹤0.01% of PrairieView Partners's portfolio in Q2 2025, its #212 holding.
PrairieView Partners first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 15 quarters since.
PrairieView Partners's Fulcrum Therapeutics position peaked at $48K in Q1 2024.
122 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2025.

Based on PrairieView Partners's 13F filing for Q2 2025, filed 25 Jul 2025.